不同剂量非布司他对3~5期慢性肾衰竭伴高尿酸血症MHD患者微炎症状态的影响

doi:10.3969/j.issn.1671-7171.2024.08.004

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1160 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effects of different doses of febuxostat on the micro-inflammatory state in patients with stage 3-5 chronic kidney disease (CKD) accompanied by hyperuricemia undergoing maintenance hemodialysis (MHD). 【Methods】A total of 114 patients undergoing MHD with stage 3-5 CKD and hyperuricemia were randomly divided into three groups: Group A (38 patients), treated with 40 mg/day of oral febuxostat; Group B (38 patients), treated with 80 mg/d of oral febuxostat; and Group C (38 patients), treated with 300 mg/d of oral allopurinol. After 24 weeks of treatment, the clinical efficacy, serum markers, and adverse drug reactions during the treatment period were compared among the three groups. 【Results】There were no statistically significant differences in clinical efficacy among the three groups (P>0.05). After treatment, the levels of serum uric acid, endothelin-1 (ET-1), interleukin-10 (IL-10), and neutrophil elastase (NE) decreased in all groups (P<0.05), but there were no statistically significant differences between the groups (P>0.05). The incidence of adverse reactions was also not significantly different among the groups (P>0.05). 【Conclusion】Different doses of febuxostat in patients undergoing MHD with stage 3-5 CKD and hyperuricemia can improve the micro-inflammatory state and reduce serum uric acid levels, with good efficacy and safety. Clinical treatment should be tailored to the specific circumstances of the patient.

Key words： Kidney Failure, Chronic/DT Gout Suppressants/AD Hyperuricacidemia Renal Dialysis

Received: 15 July 2023

PACS:

R692.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Qiong
	HUA Qi
	ZHOU Yun

Cite this article:

LIU Qiong,HUA Qi,ZHOU Yun. The Impact of Different Doses of Febuxostat on the Micro-Inflammatory State in Patients with Stage 3-5 Chronic Kidney Disease and Hyperuricemia Undergoing Maintenance Hemodialysis[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(8): 1132-1134.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.08.004 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I8/1132

[1] 张海丽,陈舜杰,王锐艳,等. 非布司他治疗老年4～5期慢性肾病伴高尿酸血症患者临床疗效[J].临床军医杂志,2021,49(1):73-74.
[2] 刘智美,王娅敏,李文巧,等. 血液透析联合HP治疗对慢性肾衰竭患者的临床疗效及对炎性因子和钙磷代谢的影响[J].西部医学,2021,33(9):1364-1368.
[3] 何立芳,阎双缓,李宏山,等. 别嘌呤醇对伴高尿酸血症糖尿病肾病患者血尿酸及尿蛋白排泄率的影响[J].河北医科大学学报,2018,39(6):649-652.
[4] 袁海,沈敏宁,卫晓菲. 非布司他逐渐增量在治疗痛风合并慢性肾脏病中的应用[J].临床肾脏病杂志,2021,21(11):918-923.
[5] 中华医学会内分泌学分会. 高尿酸血症和痛风治疗的中国专家共识[J].中华内分泌代谢杂志,2013,29(11):913-920.
[6] 张小筱,车琳,张慧,等. 非布司他抑制慢性肾脏病3～5期伴高尿酸血症患者氧化应激反应[J].中华肾脏病杂志,2019,35(9):676-683.
[7] 刘平,刘伟,秦际逵. 非布司他治疗肾移植术后高尿酸血症的临床疗效及影响因素分析[J].安徽医学,2020,41(5):530-533.
[8] 杨光辉,高艳霞,蔡宏瑜. 非布司他对慢性肾脏病3～5期伴高尿酸血症患者氧化应激反应的抑制作用[J].中国药物与临床,2021,21(12):2129-2131.
[9] 魏雪,刘蕊. 基于代谢组学技术探讨高尿酸血症合并慢性肾脏疾病的研究进展[J].天津医药,2022,50(1):108-112.
[10] 任广伟,李明明,杨洪娟,等. 非布司他对维持性血液透析伴高尿酸血症患者血清炎性因子水平和肝功能的影响[J].河北医药,2018,40(14):2171-2174.
[11] 张谊雯,张立元,过轶斌. 非布司他和别嘌呤醇治疗KDIGO分级4～5期慢性肾病伴高尿酸血症的临床效果比较[J].中国医药导报,2021,18(3):62-66.
[12] 魏晓岩,李迎婕,贾军利,等. 尿毒清颗粒联合非布司他对慢性肾脏病合并高尿酸血症患者血管内皮功能、炎症反应的影响[J].现代中西医结合杂志,2021,30(24):2655-2658.
[13] 高振宇,马艳. 高迁移率族蛋白B1、甲状旁腺素和β2-微球蛋白在血液透析联合血液灌流治疗慢性肾衰竭前后的变化及意义[J].四川医学,2019,40(3):284-287.
[14] 章娜,青玉凤,李婷,等. 非布司他联合别嘌醇治疗高尿酸血症的效果及对血清ET-1、TGF-β1水平的影响[J].中国老年学杂志,2019,39(5):1054-1057.